Development and Psychometric Evaluation of a Clinical Global Impression for Schizoaffective Disorder Scale

| January 8, 2012 | 0 Comments

 

by Michael H. Allen, MD, DFAPA; David G. Daniel, MD; Dennis A. Revicki, PhD; Carla M. Canuso, MD; Ibrahim Turkoz, MS; Dong-Jing Fu, MD, PhD; Larry Alphs, MD, PhD; K. Jack Ishak, PhD; John J. Bartko, PhD; and Jean-Pierre Lindenmayer, MD
Dr. Allen is from the Colorado Depression Center at the University of Colorado School of Medicine, Aurora, Colorado, and VISN 19 Suicide MIRECC, Denver, Colorado; Dr. Daniel is from United BioSource Corporation, McLean, Virginia; Dr. Revicki is from United BioSource Corporation, Bethesda, Maryland; Drs. Canuso and Turkoz are from Janssen Pharmaceutical Research and Development, LLC, Titusville, New Jersey; Drs. Fu and Alphs are from Janssen Scientific Affairs, LLC, Titusville, New Jersey; Dr. Ishak is from United BioSource Corporation, Dorval, Quebec, Canada; Dr. Bartko is an independent consultant, Newville, Pennsylvania; and Dr. Lindenmayer is from the New York University School of Medicine, New York, New York.

Innov Clin Neurosci. 2012;9(1):15–24

The content you are trying to view is restricted to registered members only.
Membership to Innovations in Clinical Neuroscience is free, so please consider becoming a member today.
Thank you
ICNS Online Editor
Please Login or Register for access.

Category: Drug Development, Original Research, Psychiatry, Schizophrenia, Suicidality, Trial Methodology

Leave a Reply